Summary of patient characteristics at time of ibrutinib initiation
| Characteristic . | CLL trial cohort . | Stanford University cohort . |
|---|---|---|
| Total number of patients | 16 | 11 |
| Age | ||
| Median, y | 54.5 | 59.4 |
| Range, y | 43.0-68.0 | 41.3-68.7 |
| Sex, no. (%) | ||
| Male | 11 (69) | 7 (64) |
| Female | 5 (31) | 4 (36) |
| ECOG performance status, no. (%) | ||
| 0-1 | 11 (69) | 11 (100) |
| 2 | 5 (31) | 0 (0) |
| Baseline Rai stage at initiation of ibrutinib, no. (%) | ||
| 0-II | 8 (50) | 10 (91) |
| III-IV | 7 (44) | 1 (9) |
| Unknown | 1 (6) | |
| Total number of previous therapies prior to ibrutinib initiation | ||
| Median | 5 | 5 |
| Range | 2-10 | 1-9 |
| Time from allo-HCT | ||
| Median, mo | 26.6 | 73.4 |
| Range, mo | 7.8-115.2 | 2.1-100.7 |
| Failed intervening salvage therapy between allo-HCT and the start of ibrutinib treatment, no. (%) | 12 (75) | 7 (64) |
| Bulky nodes, no. (%) | ||
| ≥5 cm in diameter | 11 (69) | 4 (36) |
| ≥10 cm in diameter | 4 (25) | 2 (18) |
| Interphase cytogenetic abnormality, no. (%) | ||
| 17p13.1 deletion | 10 (63) | 4 (36) |
| 11q22.3 deletion | 3 (19) | 4 (36) |
| Unmutated immunoglobulin variable region heavy-chain gene | Data not available | 11 (100) |
| Characteristic . | CLL trial cohort . | Stanford University cohort . |
|---|---|---|
| Total number of patients | 16 | 11 |
| Age | ||
| Median, y | 54.5 | 59.4 |
| Range, y | 43.0-68.0 | 41.3-68.7 |
| Sex, no. (%) | ||
| Male | 11 (69) | 7 (64) |
| Female | 5 (31) | 4 (36) |
| ECOG performance status, no. (%) | ||
| 0-1 | 11 (69) | 11 (100) |
| 2 | 5 (31) | 0 (0) |
| Baseline Rai stage at initiation of ibrutinib, no. (%) | ||
| 0-II | 8 (50) | 10 (91) |
| III-IV | 7 (44) | 1 (9) |
| Unknown | 1 (6) | |
| Total number of previous therapies prior to ibrutinib initiation | ||
| Median | 5 | 5 |
| Range | 2-10 | 1-9 |
| Time from allo-HCT | ||
| Median, mo | 26.6 | 73.4 |
| Range, mo | 7.8-115.2 | 2.1-100.7 |
| Failed intervening salvage therapy between allo-HCT and the start of ibrutinib treatment, no. (%) | 12 (75) | 7 (64) |
| Bulky nodes, no. (%) | ||
| ≥5 cm in diameter | 11 (69) | 4 (36) |
| ≥10 cm in diameter | 4 (25) | 2 (18) |
| Interphase cytogenetic abnormality, no. (%) | ||
| 17p13.1 deletion | 10 (63) | 4 (36) |
| 11q22.3 deletion | 3 (19) | 4 (36) |
| Unmutated immunoglobulin variable region heavy-chain gene | Data not available | 11 (100) |
ECOG, Eastern Cooperative Oncology Group.